Viewing Study NCT03078959


Ignite Creation Date: 2025-12-24 @ 2:59 PM
Ignite Modification Date: 2026-01-01 @ 7:25 AM
Study NCT ID: NCT03078959
Status: UNKNOWN
Last Update Posted: 2017-03-14
First Post: 2017-03-03
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Prognostic Value of PD-L1 in NSCLC
Sponsor: Fondazione Ricerca Traslazionale
Organization:

Study Overview

Official Title: The Prognostic Value of the Expression of Programmed Death Ligand 1 (PD-L1) in Early Stage Non-small-cell Lung Cancer
Status: UNKNOWN
Status Verified Date: 2017-03
Last Known Status: ACTIVE_NOT_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This is an observational retrospective study. The primary objective is to investigate the expression and potential prognostic role of Programmed Death Ligand 1 (PD-L1) in tumor samples from 350 patients with early stage treatment-naive non-small-cell lung cancer (NSCLC).

Tissue samples were embedded in a tissue microarray. PD-L1 will be studied by immunohistochemistry using the SP263 antibody. Stained samples will be evaluated independently by two operators. A tumor will be defined as positive when = or \>50% of tumor cells express the ligand.

The investigators will investigate the relationship between PD-L1 protein expression and overall survival and other clinical characteristics with appropriate statistical methods.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: